Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 16/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3784628 | 0.90 | TRPV1 (0.43) | TRPV1 | |
| SCHEMBL3785420 | 0.90 | TRPV1 (0.49) | TRPV1 | |
| SCHEMBL3790581 | 0.89 | TRPV1 (0.42) | TRPV1 | |
| SCHEMBL3688467 | 0.89 | TRPV1 (0.48) | TRPV1 | |
| SCHEMBL3786081 | 0.86 | TRPV1 (0.40) | TRPV1 | |
| SCHEMBL3785426 | 0.86 | TRPV1 (0.38) | TRPV1 | |
| SCHEMBL3690381 | 0.85 | NAMPT (0.35) | TRPV1 | |
| SCHEMBL3687002 | 0.85 | TRPV1 (0.34) | TRPV1P2RX7CCNT1CDK9 | |
| SCHEMBL3695902 | 0.85 | TRPV1 (0.37) | TRPV1 | |
| SCHEMBL3784894 | 0.85 | ALDH1A1 (0.37) | TRPV1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | claimed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| WO-2010091409-A1 | CERTAIN NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010091409-A1 | CERTAIN NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | OAT, HAVCR2, CPS1 | TRPV1 1682/4885P2RX7 589/4885CCNT1 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.